Offer extended until 31 July 2026: get a 10% early-bird discount on all events starting on or after 25 August 2026. To the promotion
GMP search engine – look up GMP compliance regulations and news
Falsified Medicines: MHRA publishes Class 4 FMD Medicines Information
Recommendation
8 September 2026
Basel, Switzerland
Specifics in the Distribution of Medicinal Products
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
The Medicines and Healthcare products Regulatory Agency (MHRA) is currently investigating an incident where several medicines appear to have left the legal supply chain and have then been re-introduced via WDA(H) 50340 HMS Wholesale Limited. This license has since then been terminated.
In a Falsified Medicines Directive (FMD) Alert published 19 March 2020, the MHRA says that "the products do appear to be genuine with legitimate batch numbers. These products are thought to have been stolen from the legitimate supply chain in early 2019 and reintroduced into the supply chain between May and August 2019. This means that the correct transport and storage conditions cannot be guaranteed and while unlikely, could impact their effectiveness."
Only the batch numbers mentioned in appendix 1 of the PDF are within the scope of this alert. You can download the document here.
Related GMP News
18.06.2026GDPA Participated as an Observer in the EMA GMDP-IWG Interested Parties Meeting
18.06.2026Questions and Answers from the ECA Webinar "GDP Update 2026" - Part 4
18.06.2026GDP Non-Compliance Report: Missed CAPA Timelines lead to Refusal of GDP Certificate
17.06.2026European GDP Association Developments January through April 2026
12.05.2026How Are Service Providers Qualified in a GDP Environment?
12.05.2026Questions and Answers from the ECA Webinar "GDP Update 2026" - Part 3